Please login to the form below
Scott Gottlieb
This page shows the latest Scott Gottlieb news and features for those working in and with pharma, biotech and healthcare.
UPDATED: Senate officially confirms Stephen Hahn as FDA commissioner
He was also backed by previous FDA commissioner Scott Gottlieb, who endorsed Sharpless as “an outstanding physician and scientist who is deeply committed to public health goals” who he hoped would
Latest news
-
Mega-mergers dominate as buoyant markets lift biopharma
now former FDA commissioner Scott Gottlieb.
-
FDA will maintain the pace, vows Woodcock, but warns of skills gap
Top official unconcerned by dip in approval rate. The departure of Scott Gottlieb in April robbed the FDA of one of its most dynamic ever Commissioners, and industry observers have been ... Before Gottlieb departed earlier this year, he unveiled a new
-
Ex-FDA chief Gottlieb's quick move to pharma raises eyebrows
Will join Pfizer board. Just 83 days after leaving his Commissioner role at the FDA, Scott Gottlieb has joined the board of big pharma group Pfizer. ... We are fortunate to have D. Gottlieb join Pfizer’s Board of Directors,” said Pfizer executive
-
Verily unveils next-gen trials alliance with Novartis, Pfizer
There is also no doubt that regulators are keen to see the industry update its practices. Shortly before he stepped down as FDA commissioner earlier this year, Scott Gottlieb expressed his
-
Sanofi joins Lilly in insulin price cut, but lawmakers have lost patience
Last week, outgoing FDA Commissioner Scott Gottlieb said the regulator would change how insulin is regulated to make it easier for biosimilar insulin products to come to market.
More from news
Approximately 5 fully matching, plus 44 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
He replaced Scott Gottlieb, who was popular with industry but resigned from the post unexpectedly last year, as well as stand-in Ned Sharpless who has now returned to his post
-
Will biosimilars ever catch on in the US?
In the early days of the Trump administration, then-FDA commissioner Scott Gottlieb made a point of clearing the way for even faster and more generic approvals, again with some apparent ... Based on those assumed savings, had all the FDA-approved
-
Encouraging signs in biomarker R&D
The timing of the withdrawal was ironic given that, in the same month, FDA Commissioner Scott Gottlieb highlighted ‘TMB as a potential biomarker for enriching clinical trials testing immunotherapies’. ... Harmonisation. Gottlieb has since resigned,
-
Streamlining clinical trials – why better data use is key
Dr Scott Gottlieb’s brief, energetic tenure as US FDA Commissioner is likely to shape agency oversight of the pharmaceutical industry for years to come, particularly in relation to clinical development. ... To embrace innovations like blockchain, as
-
Cell and gene therapy
Interest in cell and gene therapies is undeniable. In January, US FDA Commissioner Scott Gottlieb outlined policies designed to accommodate an anticipated surge in cell and gene therapy submissions. ... Gottlieb highlighted manufacture as a challenge
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Regeneron says antibody for COVID-19 could be ready this year
- Imperial College London to lead major coronavirus home testing programme
- Octapharma cleared to start phase 3 trial of Octagam in COVID-19
- Biogen delays filing of Alzheimer’s drug, which hits its share price
- Octapharma cleared to start phase 3 trial of Octagam in COVID-19
- Novartis to test canakinumab for COVID-19, as IL-6 trial disappoints
- ACCOMPLISH MEANINGFUL HCP ENGAGEMENT ONLINE
- New data backs remdesivir for COVID-19, but rings hydroxychloroquine alarm bell
- EPI-backed coronavirus vaccine from Novavax starts trials
- NICE approves Roche’s Tecentriq in TNBC after revising deal
- Effectively communicating in a public health crisis
- DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
PMHub
Cuttsy + Cuttsy
How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...
Latest intelligence
- ACCOMPLISH MEANINGFUL HCP ENGAGEMENT ONLINE
- The art of delivering valuable customer journeys aligned to your key messages in 2020...
- DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
- This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
- Why are new medicinal products denied reimbursement in France?
- Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...
Quick links
Infographics
